Incannex's IHL-42X Wins MedTech Breakthrough Award, Validating Sleep Apnea Therapy

Event summary

  • Incannex Healthcare's IHL-42X won 'Best New Technology Solution for Drug Development' at the 10th annual MedTech Breakthrough Awards on May 12, 2026.
  • IHL-42X is an oral fixed-dose combination therapy for obstructive sleep apnea (OSA), combining dronabinol and acetazolamide.
  • Phase 2 RePOSA trial showed statistically significant reductions in apnea-hypopnea index (AHI) and improvements in oxygenation and sleep quality.
  • Incannex is advancing IHL-42X through late-stage development, targeting a first-in-class oral therapy for OSA.

The big picture

The award underscores Incannex's position in next-generation therapeutic innovation, particularly in addressing unmet medical needs in OSA. The recognition comes amid increasing global competition in digital health and medical technology, highlighting the company's strategy of developing differentiated combination therapies. With a growing body of clinical data, Incannex is poised to advance IHL-42X through late-stage development, potentially redefining the treatment paradigm for millions of patients worldwide.

What we're watching

Clinical Progression
How the Phase 2 results will translate into late-stage development and regulatory approval timelines for IHL-42X.
Market Differentiation
Whether IHL-42X can establish itself as a first-in-class oral therapy in the competitive OSA treatment landscape.
Strategic Expansion
The pace at which Incannex can leverage this validation to explore partnerships or commercialization opportunities for IHL-42X.